Literature DB >> 30709684

Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?

Chunyan Sun1, Xiao Xiao2, Li Yan3, Li Sheng4, Qixia Wang5, Pan Jiang6, Min Lian7, Yanmei Li8, Yiran Wei9, Jun Zhang10, Yong Chen6, Bo Li11, You Li6, Binyuan Huang6, Yikang Li6, Yanshen Peng12, Xiaoyu Chen6, Jingyuan Fang13, Dekai Qiu6, Jing Hua6, Ruqi Tang14, Patrick Leung15, M Eric Gershwin16, Qi Miao17, Xiong Ma18.   

Abstract

BACKGROUND AND AIMS: The most highly directed and specific autoantibody in human immunopathology is the serologic hallmark of primary biliary cholangitis (PBC), antimitochondrial antibodies (AMAs). However the clinical significance of finding a positive AMA, with normal alkaline phosphatase (ALP) remains enigmatic.
METHODS: We took advantage of 169 consecutive outpatients who were identified as having a positive AMA, but normal ALP levels between January 2012 and January 2018. A liver biopsy was performed on 67/169 of these AMA positive normal ALP patients.
RESULTS: In all 169 patients we reconfirmed the AMA and also performed anti-gp210 and anti-sp100, liver stiffness (LSM) assessed by vibration-controlled transient elastography (VCTE), an abdominal computed tomography (CT) scan, and either a magnetic resonance imaging (MRI) or ultrasound. The liver biopsies were reviewed by two unbiased observers. 87.6% of the 169 patients were females with a mean age of 46; the median AMA titer 1:320; an elevated serum IgM was found in 53.3%. Importantly, in patients with a liver biopsy, 55(82.1%)out of 67 had varying degrees of cholangitis activity, diagnostic of PBC.
CONCLUSION: In patients who were AMA-positive but had normal ALP levels, more than 80% were associated with histological classic PBC. These data emphasize the importance of a positive AMA, even with a normal ALP and also question the role of ALP as a sole surrogate marker of cholangitis.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Alkaline phosphatase; Antimitochondrial antibody; Cholangitis activity; Histology; Primary biliary cholangitis

Mesh:

Substances:

Year:  2019        PMID: 30709684     DOI: 10.1016/j.jaut.2019.01.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection.

Authors:  Honglian Gui; Weijing Wang; Qing Li; Ziqiang Li; Jie Lu; Qing Xie
Journal:  Immunol Res       Date:  2021-01-28       Impact factor: 2.829

Review 2.  Current understanding of primary biliary cholangitis.

Authors:  Atsushi Tanaka
Journal:  Clin Mol Hepatol       Date:  2020-12-03

Review 3.  Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers.

Authors:  Mirjam Kolev; Michael P Horn; Nasser Semmo; Michael Nagler
Journal:  J Transl Autoimmun       Date:  2022-03-06

4.  Immunoglobulin M: A Neglected Serum Biomarker in Treatment-Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase.

Authors:  Dawei Ding; Guoyun Xuan; Yinan Hu; Jiahao Yu; Yansheng Liu; Guanya Guo; Shuoyi Ma; Fangfang Yang; Siyuan Tian; Gang Ma; Ling Chen; Xinmin Zhou; Yulong Shang; Ying Han
Journal:  Hepatol Commun       Date:  2022-02-19

5.  The gut microbiome contributes to splenomegaly and tissue inflammation in a murine model of primary biliary cholangitis.

Authors:  Cheng-Bo Wang; Yan Wang; Yuan Yao; Jin-Jun Wang; Koichi Tsuneyama; Qiong Yang; Bin Liu; Carlo Selmi; M Eric Gershwin; Shu-Han Yang; Zhe-Xiong Lian
Journal:  Ann Transl Med       Date:  2022-05

6.  Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis.

Authors:  Naidan Zhang; Chaixia Ji; Xiao Bao; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

7.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.